MGF Research# MGF research originates primarily from the laboratory of Geoffrey Goldspink at University College London: Discovery and characterization : First described in the late 1990s as a mechanically sensitive IGF-1 splice variant in rabbit and human skeletal muscle Satellite cell activation : Demonstrated ability to activate quiescent satellite cells in culture, with evidence for IGF-1R-independent signaling Cardiac applications : Expression of IGF-1Ec documented in cardiac muscle following myocardial infarction, with preclinical evidence for cardioprotective effects Neuroprotection : MGF expression detected in brain tissue following ischemic injury, with preliminary evidence for neuronal survival effects Aging research : Impaired MGF upregulation documented in elderly subjects after exercise, suggesting a mechanism for age-related decline in regenerative capacity MGF remains entirely preclinical, with no human clinical trials
*Removes excess oil, based on clinical tests
Once blood clots block veins, you get limited oxygen and are prone to respiratory issues
While supplementation with exogenous GSH has shown therapeutic potential on its own, recent findings indicate advantages to combined treatment with other immunomodulatory or anti-infective agents (Vairetti et al., 2021)
Only when raw materials meet Life Extensions specifications are they released for production
Interpretability of AI models The interpretability of AI models presents another critical challenge